Lymphocytic Leukemia, Chronic Clinical Trial
Official title:
Feasibility/Phase II Trial of Fludarabine, Rituximab, and Alemtuzumab for Previously Treated B-Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
This purpose of this study is to assess the toxicity and the rate of complete and overall response using fludarabine, rituximab, and alemtuzumab to treat patients with B-chronic lymphocytic leukemia or small lymphocytic leukemia who have received previous treatment.
Immunotherapy, or treatments that work by boosting immune function in the body, such as
monoclonal antibodies have shown some efficacy against different types of leukemia.
Researchers have learned to manufacture antibodies outside of the human body that can bind
to specific targets in cancer cells. Monoclonal antibodies are designed to recognize
different proteins on specific cancer cells. The current study combines two monoclonal
antibodies, rituximab and fludarabine. Rituximab attaches to a protein called the CD20
antigen that is found almost exclusively on the surface of B-cells with leukemia. Once
rituximab attaches to the protein, the immune system activates to kill the malignant
B-cells. Alemtuzumab works in a similar way by attaching with the CD25 antigen and also has
activity in patients with p53 gene mutations. Previous studies indicate that both rituximab
and alemtuzumab separately have some efficacy against lymphocytic leukemia. Research has
also shown that fludarabine works against the disease. Rituximab and fludarabine in
combination appear to have a high response rate in patients. Researchers are seeking to
improve efficacy data by adding alemtuzumab to the combination of rituximab and fludarabine
in this study.
This study will evaluate the safety and efficacy of fludarabine, rituximab, and alemtuzumab
in patients with previously treated B-cell lymphocytic leukemia and small lymphocytic
leukemia. Blood and bone marrow tests will assess genetic features associated with response
to therapy, immune recovery, mechanisms of alemtuzumab's signaling, routes of drug
resistance, and traces of residual disease following complete response in patients.
Patients in this study will receive fludarabine, rituximab, and alemtuzumab. These drugs
will be administered through intravenous infusions. The treatment period will last 22 weeks.
Fludarabine will not be given during week one, 5 days during week 2, and 5 days during weeks
6, 10, 14, 18, and 22. Rituximab will not be given during week one, 3 times the second week,
and day one of weeks 6, 10, 14, 18, and 22. Alemtuzumab will be given 3 times during week
one, once during week 2, and day 2 of weeks 6, 10, 14, 18, and 22. The dosage amount of
rituximab and alemtuzumab will be increased depending upon the degree of side effects.
Several tests and exams will be given throughout the study to closely monitor patients.
Treatments will be discontinued due to disease growth or unacceptable side effects.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01072240 -
An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia
|
N/A | |
Completed |
NCT00754650 -
A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia
|
Phase 2 | |
Active, not recruiting |
NCT02500407 -
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04704323 -
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
|
||
Active, not recruiting |
NCT01414205 -
A Study Comparing RO5072759 (GA101) 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GAGE)
|
Phase 2 | |
Completed |
NCT01224093 -
An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)
|
N/A | |
Completed |
NCT01395615 -
An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia
|
N/A | |
Completed |
NCT00532129 -
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
|
Phase 2 | |
Completed |
NCT02013817 -
CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
|
Phase 2 | |
Completed |
NCT01685892 -
A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT00738374 -
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
|
Phase 2 | |
Completed |
NCT00241358 -
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT01056510 -
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
|
Phase 4 | |
Completed |
NCT01300247 -
A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)
|
Phase 1 | |
Terminated |
NCT01271010 -
A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status
|
Phase 4 | |
Completed |
NCT00718549 -
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
|
Phase 3 | |
Completed |
NCT01263704 -
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT00431873 -
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT01178086 -
A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
|
||
Terminated |
NCT02292225 -
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
|
Phase 1 |